Rigosertib, Catalog: 9482

Alternate Names Sodium (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetate; ON-01910

Appearance White solid

CAS # 1225497-78-8

Molecular Formula C₂₁H₂₄NNaO₈S

Molecular Weight 473.47

Purity ≥ 98% by HPLC

Solubility DMSO (>5 mg/ml)

SMILES COC1=C(C=C(C=C1)CS(=O)(=O)C=CC2=C(C=C(C=C2OC)OC)OC)NCC(=O)[O-].[Na+]

InChi InChI=1S/C21H25NO8S.Na/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24;/h5-11,22H,12-13H2,1-4H3,(H,23,24);/q;+1/p-1/b8-7+;

InChi Key VLQLUZFVFXYXQE-USRGLUTNSA-M

PubChem CID 23696523

Storage Conditions -20°C

Shipping Conditions Gel Pack

USAGE For Research Use Only! Not For Use in Humans.

Handling Do not take it internally. Wear a glove and mask when handling the product. Protect from air, light and moisture.

Rigosertib is a potent, specific PLK1 (Polo -Like Kinase 1) inhibitor (IC₅₀ = 9 nM). Rigosertib strongly inhibits the proliferation of cancer cell lines, with observed IC₅₀ values in the nanomolar range for both HeLa (115 nM) and C33A (45 nM) cells. In contrast, Rigosertib has a minimal effect on normal cell lines, BJ and Ect1/E6E7 (IC₅₀ > 0.1 mM).